Scientific publications for BioPredictive non-invasive diagnostics

Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.

70/433 Matches for
“Steato test”

“Steato test” Clear all
  1. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. Key publication

    Poynard T et al. · BMC Gastroenterol · 2006 Match 100

    …new biomarker of non alcoholic steato hepatitis (NASH) the NashTest (NT) in…

    NashTest Metabolic

  2. Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The "VARES" Italian multicenter study.

    Grattagliano I et al. · Ann Hepatol · 2013 Match 100

    The diagnostic utilities of ultrasonography (US), fatty liver index (FLI) and an…

    ActiTest FibroTest NashTest SteatoTest +1

  3. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data.

    Poynard T et al. · PLoS One · 2012 Match 99

    …fibrosis (FibroTest), steatosis (SteatoTest) and steato-hepatitis (NashTest, ActiTest) in these patients…

    ActiTest FibroTest NashTest SteatoTest +1

  4. Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2020 Match 98

    …fibrosis stages, steatosis and nonalcoholic-steato-hepatitis (NASH) grades use an ordinal…

    FibroTest NashTest-2 SteatoTest-2 Metabolic

  5. The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests.

    Netanel C et al. · Am J Surg · 2021 Match 98

    …Data collected included anthropometrics, biochemistry, adiponectin, SteatoTest™, NashTest™, FibroTest™, OWLiver® test and…

    FibroTest NashTest SteatoTest Metabolic

  6. Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia.

    Poynard T et al. · Hepatol Commun · 2023 Match 97

    ### Background And Aims Gilbert syndrome (GS) is genotypically predetermined by UGT1A1*28…

    FibroTest

  7. [The diagnostic value of non-invasive biochemical biomarkers in alcohol abuse].

    Supronowicz Ł et al. · Pol Merkur Lekarski · 2013 Match 96

    …The probability of a positive test results of Steato Test and FibroTest…

    AshTest FibroTest SteatoTest Alcohol

  8. The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease.

    Thabut D et al. · J Hepatol · 2006 Match 95

    …for the diagnosis of alcoholic steato-hepatitis (ASH), in patients with chronic…

    AshTest Alcohol

  9. Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population.

    Zelber-Sagi S et al. · Transl Res · 2015 Match 95

    Retrospective studies suggest that coffee consumption may exert beneficial effects in patients…

    FibroTest SteatoTest Metabolic

  10. Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes.

    Poynard T et al. · Aliment Pharmacol Ther · 2021 Match 94

    ### Background One of the unmet needs in patients with type 2 diabetes…

    FibroTest NashTest-2 SteatoTest Metabolic

  11. The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women.

    Simental-Mendía LE et al. · Ann Hepatol · 2016 Match 93

    …showed to be the best test for screening. ### Conclusions TyG has high…

    NashTest SteatoTest Metabolic

  12. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.

    de Lédinghen V et al. · Liver Int · 2012 Match 93

    ### Introduction Recently, a study showed that Controlled Attenuation Parameter (CAP), evaluated with…

    SteatoTest Metabolic

  13. Fibrotest-Actitest: the biochemical marker of liver fibrosis--the Israeli experience.

    Morali G et al. · Isr Med Assoc J · 2007 Match 92

    …This test has been validated by several studies in hepatitis B and…

    ActiTest FibroTest Alcohol HBV +1

  14. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Comp Hepatol · 2005 Match 91

    ### Background Biopsy is the usual gold standard for liver steatosis assessment. The…

    SteatoTest Alcohol HBV HCV +1

  15. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Key publication

    Ratziu V et al. · BMC Gastroenterol · 2006 Match 90

    ### Background Liver biopsy is considered as the gold standard for assessing non…

    FibroTest Metabolic

  16. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.

    Vilar-Gomez E et al. · J Hepatol · 2018 Match 90

    The correct identification of patients at increased risk of non-alcoholic steatohepatitis…

    FibroTest Metabolic

  17. Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review

    Bril F et al. · Diabetes Care · 2017 Match 89

    Traditionally a disease of hepatologists, nonalcoholic fatty liver disease (NAFLD) has recently…

    FibroTest Metabolic

  18. Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease.

    Viglino D et al. · Eur Respir J · 2017 Match 88

    Nonalcoholic fatty liver disease (NAFLD) is independently linked to cardiometabolic morbidity and…

    FibroTest NashTest SteatoTest Metabolic

  19. Editorial: FibroTest to predict liver-related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?

    Bush AM et al. · Aliment Pharmacol Ther · 2018 Match 88

    FibroTest Metabolic

  20. First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy.

    Poynard T · J Hepatol · 2011 Match 87

    ActiTest AshTest FibroTest NashTest +7

  21. Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea.

    Minville C et al. · Chest · 2014 Match 86

    ### Background Nocturnal hypoxia, the hallmark of OSA, is a potential contributing factor…

    FibroTest NashTest SteatoTest Metabolic

  22. FibroMAX: towards a new universal biomarker of liver disease?

    Morra R et al. · Expert Rev Mol Diagn · 2007 Match 85

    Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…

    ActiTest AshTest FibroTest NashTest +7

  23. Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods.

    Festi D et al. · Aliment Pharmacol Ther · 2013 Match 85

    ### Background Non-alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of…

    SteatoTest

  24. Impact of steatosis and inflammation definitions on the performance of NASH tests.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Match 84

    …The simplified definition increased the κ concordance (P<0.0001) between test

    ActiTest FibroTest NashTest NashTest-2 +3

  25. Silymarin in non alcoholic fatty liver disease.

    Cacciapuoti F et al. · World J Hepatol · 2013 Match 83

    …On the contrary, Steato test, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and…

    SteatoTest Metabolic

  26. Prospective evaluation of FibroTest®, FibroMeter®, and HepaScore® for staging liver fibrosis in chronic hepatitis B: comparison with hepatitis C.

    Leroy V et al. · J Hepatol · 2014 Match 83

    ### Background & Aims Fibrosis blood tests have been validated in chronic hepatitis C…

    FibroTest HBV HCV

  27. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.

    Zelber-Sagi S et al. · World J Gastroenterol · 2013 Match 82

    ### Aim To compare noninvasive methods presently used for steatosis detection and quantification…

    SteatoTest Metabolic

  28. [Prognosis assessment of alcoholic liver disease: how and why?].

    Trabut JB et al. · Presse Med · 2014 Match 81

    Alcoholic liver disease (ALD) causes more than 5000 deaths per year in…

    FibroTest Alcohol

  29. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.

    Munteanu M et al. · Aliment Pharmacol Ther · 2016 Match 80

    …FIB4 and NAFLD scores (Bonferroni test P < 0.05). ### Conclusions In patients…

    ActiTest FibroTest SteatoTest Metabolic

  30. The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2019 Match 80

    …The performance of the SteatoTest-2 was compared with the reference test

    NashTest-2 SteatoTest-2 Metabolic

  31. The Distribution of Liver Steatosis, Fibrosis, Steatohepatitis and Inflammation Activity in Alcoholics According to FibroMax Test.

    Gudowska M et al. · Adv Clin Exp Med · 2015 Match 79

    ### Background The diagnosis of alcoholic liver diseases is based on the history…

    ActiTest AshTest FibroTest NashTest +2

  32. Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes.

    Jacqueminet S et al. · Clin Gastroenterol Hepatol · 2008 Match 78

    ### Background & Aims Patients with diabetes are at risk for nonalcoholic fatty liver…

    FibroTest SteatoTest Metabolic

  33. Non-invasive markers of liver fibrosis in chronic liver disease in a group of Mexican children. A multicenter study.

    Flores-Calderón J et al. · Ann Hepatol · 2012 Match 78

    ### Introduction Identifying liver fibrosis is important to evaluate the severity of liver…

    FibroTest

  34. Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.

    Denimal D et al. · Cardiovasc Diabetol · 2025 Match 77

    …a non-invasive liver fibrosis test and the progression of lower limb…

    ActiTest FibroTest NashTest SteatoTest +1

  35. Biomarkers of liver fibrosis.

    Poynard T et al. · Adv Clin Chem · 2008 Match 76

    …FibroTest (FT) was the most studied test with 33 different populations including…

    ActiTest FibroTest SteatoTest Alcohol +5

  36. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.

    Sebastiani G et al. · Aliment Pharmacol Ther · 2011 Match 75

    ### Background Performance of non-invasive fibrosis biomarkers may be influenced by aetiology…

    FibroTest HBV HCV HIV +1

  37. Glycogenic hepatopathy.

    Khoury J et al. · Hepatobiliary Pancreat Dis Int · 2018 Match 75

    ### Background Glycogenic hepatopathy (GH) is a disorder associated with uncontrolled diabetes mellitus…

    FibroTest Metabolic

  38. Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease.

    Viglino D et al. · Sci Rep · 2018 Match 74

    Chronic Obstructive Pulmonary Disease (COPD) and Non-Alcoholic Fatty Liver Disease (NAFLD…

    FibroTest NashTest SteatoTest Metabolic

  39. Comparative diagnostic study of biomarkers using FibroMax™ and pathology for prediction of liver steatosis in patients with chronic hepatitis C virus infection: an Egyptian study.

    Fouad A et al. · Int J Gen Med · 2013 Match 73

    ### Background Steatosis is common in patients with hepatitis C virus (HCV) infection…

    HCV

  40. Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials.

    Jullian-Desayes I et al. · Respirology · 2016 Match 73

    …effective CPAP on the FibroMax test (comprising components including the SteatoTest, NashTest…

    NashTest SteatoTest Metabolic

  41. Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers.

    Friedrich-Rust M et al. · J Clin Gastroenterol · 2010 Match 72

    ### Background In recent years noninvasive methods have been evaluated for the assessment…

    FibroTest SteatoTest Other

  42. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.

    Lassailly G et al. · Eur J Gastroenterol Hepatol · 2011 Match 71

    ### Background Liver biopsy is considered as the gold standard for assessing nonalcoholic…

    FibroTest NashTest SteatoTest Metabolic

  43. Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers.

    Vermehren J et al. · BMC Gastroenterol · 2012 Match 70

    ### Background Liver fibrosis in human immunodeficiency virus (HIV)-infected individuals is mostly…

    FibroTest HCV HIV

  44. Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients.

    Bourliere M et al. · Aliment Pharmacol Ther · 2008 Match 70

    ### Background Non-invasive liver fibrosis scores such as Hepascore (HS) have been…

    FibroTest HCV

  45. Noninvasive Markers of Improvement of Liver Steatosis Achieved by Weight Reduction in Patients with Nonalcoholic Fatty Liver Disease.

    Copaci I et al. · Rom J Intern Med · 2015 Match 69

    ### Unlabelled Nonalcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance…

    SteatoTest Metabolic

  46. Relationship between the Fibrotest and portal hypertension in patients with liver disease.

    Thabut D et al. · Aliment Pharmacol Ther · 2007 Match 68

    ### Background The best technique to estimate portal hypertension (PHT) is to measure…

    FibroTest Alcohol HBV HCV +2

  47. Performances of Elasto-FibroTest(®), a combination between FibroTest(®) and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C.

    Poynard T et al. · Clin Res Hepatol Gastroenterol · 2012 Match 68

    …the performance of a new test the Elasto-FibroTest(®) (EFT) combining FibroTest…

    Elasto-FibroTest FibroTest HCV

  48. Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis.

    Rudler M et al. · PLoS One · 2015 Match 67

    …The blood test AshTest (BioPredictive, Paris, France) has been initially validated for…

    AshTest Alcohol

  49. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.

    Lemoine M et al. · J Acquir Immune Defic Syndr · 2019 Match 66

    ### Background HIV-monoinfected individuals are at high risk of nonalcoholic fatty liver…

    FibroTest NashTest SteatoTest HIV

  50. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Key publication

    Naveau S et al. · Hepatology · 2009 Match 65

    FibroTest has been validated as a biomarker of fibrosis in patients with…

    ActiTest AshTest FibroTest Alcohol

  51. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.

    Pais R et al. · Eur J Intern Med · 2015 Match 65

    ### Unlabelled The association of NAFLD with chronic hepatitis C (CHC) has been…

    FibroTest SteatoTest HBV HCV +1

  52. Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes.

    Meritsi A et al. · Clin Diabetes · 2022 Match 64

    ActiTest FibroTest NashTest-2 Metabolic

  53. Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison.

    Poynard T et al. · PLoS One · 2016 Match 63

    ### Background And Aims Real-time shear wave elastography (2D-SWE) is a…

    ActiTest FibroTest SteatoTest Alcohol +3

  54. EASL clinical practical guidelines: management of alcoholic liver disease.

    European Association for the Study of Liver · J Hepatol · 2012 Match 63

    FibroTest Alcohol

  55. Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests. Key publication

    Nguyen-Khac E et al. · Aliment Pharmacol Ther · 2008 Match 62

    ### Background Systematic screening for liver fibrosis in heavy-drinking patients is a…

    FibroTest Alcohol

  56. Meta-analyses of FibroTest diagnostic value in chronic liver disease.

    Poynard T et al. · BMC Gastroenterol · 2007 Match 61

    …The aim was to test two hypotheses, one, that the FT diagnostic…

    FibroTest Alcohol HBV HCV +1

  57. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C.

    Poynard T et al. · Comp Hepatol · 2004 Match 60

    …only as a second line test, i.e., in case of high…

    ActiTest FibroTest HCV

  58. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).

    Poynard T et al. · BMC Gastroenterol · 2010 Match 60

    ### Background FibroTest and elastography have been validated as biomarkers of liver fibrosis…

    FibroTest Alcohol HBV HCV +3

  59. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. Review

    Moreno C et al. · J Hepatol · 2019 Match 59

    …The commercially available Enhanced Liver Fibrosis test and FibroTest have comparable performance…

    FibroTest Alcohol

  60. Noninvasive evaluation of NAFLD.

    Castera L et al. · Nat Rev Gastroenterol Hepatol · 2013 Match 58

    A common clinical concern in patients with NAFLD is whether they have…

    ActiTest FibroTest NashTest SteatoTest +1

  61. Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

    Poynard T et al. · Diagnostics (Basel) · 2025 Match 58

    **Background/Objectives:** Bariatric surgery (BS), drugs approved for type-2-diabetes (T2D…

    FibroTest-T2D Metabolic

  62. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Key publication

    Halfon P et al. · Gastroenterol Clin Biol · 2008 Match 57

    FibroTest (FT) is a biomarker of liver fibrosis initially validated in patients…

    FibroTest Alcohol HBV HCV +2

  63. Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis.

    Poynard T et al. · Aliment Pharmacol Ther · 2023 Match 56

    FibroTest-T2D NashTest-T2D SteatoTest-T2D Metabolic

  64. Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. Key publication

    Poynard T et al. · PLoS One · 2020 Match 55

    ### Background Since 1920, a decrease in serum cholesterol has been identified as…

    FibroTest COVID

  65. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation.

    Ahmad W et al. · Virol J · 2011 Match 55

    …based on simplest routine laboratory test. Genetic marker in combination of imaging…

    FibroTest HCV

  66. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.

    Younossi ZM et al. · Gastroenterology · 2021 Match 54

    ### Background & Aim Fibrosis is an independent predictor of death in nonalcoholic steatohepatitis…

    FibroTest Metabolic

  67. EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

    European Association for the Study of the Liver · J Hepatol · 2011 Match 53

    ActiTest FibroTest HCV

  68. Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.

    Deckmyn O et al. · Biomedicines · 2022 Match 53

    In patients with non-alcoholic fatty liver disease (NAFLD) with or without…

    FibroTest Metabolic

  69. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication

    European Association for Study of Liver et al. · J Hepatol · 2015 Match 52

    FibroTest Alcohol HBV HCV +3

  70. Ministère des Affaires Sociales et de la Santé Key publication

    Match 51

    FibroTest HBV HCV

Showing the full result list. The page is server-rendered and not paginated.